tiprankstipranks
Trending News
More News >
Atossa Therapeutics, Inc. (GB:0HJ7)
:0HJ7
Advertisement

Atossa Therapeutics (0HJ7) Price & Analysis

Compare
0 Followers

0HJ7 Stock Chart & Stats

Currently, no data available
Please return soon. This page is being updated.

Bulls Say, Bears Say

Bulls Say
Clinical TrialsPositive topline data from the KARISMA-Endoxifen Phase 2 study demonstrated that low doses of (Z)-endoxifen significantly reduced mammographic breast density and was well tolerated.
Intellectual PropertyAtossa bolstered its intellectual property portfolio with new patents for endoxifen, strengthening its market position.
Market PotentialThe market potential of approximately a billion dollars presents high rewards for these risks.
ValuationThe current valuation is considered attractive, maintaining a BUY rating and raising the 12-month price target to $7.50, indicating significant upside potential.
Bears Say
CompetitionThe oral SERD space in second-line and beyond patients has become increasingly competitive, though to date, Phase 3 trials have only indicated a benefit in ESR1 mutant patients.
Regulatory ChallengesWhile there are high risks due to the long development road and potential for clinical trial failures, the market potential presents high rewards for these risks.

Financials

Options Prices

Currently, No data available
---

Ownership Overview

3.41%7.85%0.28%79.93%
7.85%
Mutual Funds
0.28% Other Institutional Investors
79.93% Public Companies and Individual Investors

0HJ7 FAQ

What was Atossa Therapeutics, Inc.’s price range in the past 12 months?
Currently, no data Available
What is Atossa Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Atossa Therapeutics, Inc.’s upcoming earnings report date?
Atossa Therapeutics, Inc.’s upcoming earnings report date is Aug 18, 2025 which is in 30 days.
    How were Atossa Therapeutics, Inc.’s earnings last quarter?
    Atossa Therapeutics, Inc. released its earnings results on May 13, 2025. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.057 by $0.007.
      Is Atossa Therapeutics, Inc. overvalued?
      According to Wall Street analysts Atossa Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does Atossa Therapeutics, Inc. pay dividends?
        Atossa Therapeutics, Inc. does not currently pay dividends.
        What is Atossa Therapeutics, Inc.’s EPS estimate?
        Atossa Therapeutics, Inc.’s EPS estimate is -0.06.
          How many shares outstanding does Atossa Therapeutics, Inc. have?
          Currently, no data Available
          What happened to Atossa Therapeutics, Inc.’s price movement after its last earnings report?
          Atossa Therapeutics, Inc. reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.057. Following the earnings report the stock price went same N/A.
            Which hedge fund is a major shareholder of Atossa Therapeutics, Inc.?
            Currently, no hedge funds are holding shares in GB:0HJ7

            Company Description

            Atossa Therapeutics, Inc.

            Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

            0HJ7 Company Deck

            0HJ7 Earnings Call

            Q4 2025
            0:00 / 0:00
            Earnings Call Sentiment|Positive
            The earnings call presented a generally positive outlook with notable reductions in operating costs and promising clinical advancements for (Z)-endoxifen, particularly in metastatic breast cancer. However, the financial impact of a write-off and decreased interest income offset some of these positives.Read More>

            0HJ7 Stock 12 Month Forecast

            Average Price Target

            $5.63
            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
            Similar Stocks
            Company
            Price & Change
            Follow
            Anixa Biosciences
            Pliant Therapeutics
            Senti Biosciences
            Zura Bio
            HilleVax, Inc
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis